Definium Therapeutics, Inc. Common Shares closed at $32.70 on Nov 4, down 2.13%, 32.5% below its highest close since Jan 15. Volume of 1.4M shares was 0.74× its 20-day average (below normal).
Split-adjusted performance: -8.2% over one month, +39.6% over six months.
Short interest was 10.0M shares at the Oct 15 settlement, down 11.5% from the prior report (7.6% of float, 4.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DFTXDefinium Therapeutics | $32.70 | −2.13% | +39.6% | — | — | — | $4.39B | |
| ARQTArcutis Biotherapeutics | $34.05 | +6.41% | +40.9% | +59.3% | 11.6% | 150.1 | $4.28B | Compare |
| LQDALiquidia | $47.38 | +12.27% | +12.4% | +1842.7% | 43.5% | 30.6 | $4.24B | Compare |
| EWTXEdgewise Therapeutics | $37.53 | −0.40% | +1.5% | — | — | — | $4.08B | Compare |
| DNTHDianthus Therapeutics | $85.81 | +3.76% | −5.1% | +294.3% | −6598.6% | — | $4.80B | Compare |
| ABCLAbCellera Biologics | $12.28 | +0.82% | +143.7% | −76.3% | −1368.6% | — | $3.98B | Compare |
| TNGXTango Therapeutics | $23.18 | +0.04% | −1.9% | −100.0% | — | — | $3.91B | Compare |
| TVTXTravere Therapeutics | $52.42 | +6.09% | +17.1% | +36.2% | −23.3% | — | $4.94B | Compare |
| XENEXenon Pharmaceuticals | $39.19 | +2.51% | −33.1% | — | — | — | $3.80B | Compare |
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
